All News

RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

Read Article
warning, caution

EMA Crack Down on JAK Inhibitors

Jack Cush, MD

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Read Article
biosimilars2.jpg

Growing Confidence in Biosimilars?

MediaSource

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

Read Article
risk.time_.jpg

Increasing Prevalence of RA, PsA and AS in the UK

Jack Cush, MD

Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.

Read Article
morbidity,covid,heart,lung,brain

No Special Heart Risk With JAK Inhibitors, Study Finds

MedPage Today

Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.

Read Article
choices2.jpg

IL-17 Switching Works in Psoriatic Disease

Jack Cush, MD

Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.

Read Article
JAK Janus

Efficacy and Safety of JAK Inhibitors in Psoriatic Disease

Jack Cush, MD

There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe psoriasis and psoriatic arthritis, according to a systematic review in BMC Rheumatology.

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Jack Cush, MD

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.

Read Article
Multinatinal cross-sectional survey of 2270 PsA pts shows despite comparable Dz duration, presentation, biologic use (54%), Women had worse QOL, more disability and work activity impairment (but less comorbidities) https://t.co/1KbDuxaMFf https://t.co/SsbSHQNsPV

Links:

Dr. John Cush RheumNow ( View Tweet)
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
Will we see you there? #ACR2022 What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
Increasing Prevalence of RA, PsA and AS in the UK Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), PsA and SpA patients in England. https://t.co/Rtt5dvFc17 https://t.co/rPsvq3nlXl

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Salaries and Career Choices A recent Doximity report shows how rheumatology salaries increase by years in practice. Rheumatologists tend to earn their highest salaries after gaining 30-39 years of experience. https://t.co/wxWQruIlu9 https://t.co/gUsIffoHn6

Links:

Dr. John Cush RheumNow ( View Tweet)
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY

Links:

Dr. John Cush RheumNow ( View Tweet)
Record a Question or Comment... Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/5upWNItwGy https://t.co/RMwDYVubOk

Links:

Dr. John Cush RheumNow ( View Tweet)
Is there a link between PsA & autoinflammatory disease? Dr. Cush reviews a recent study of 120 #PsA patients in our latest podcast. https://t.co/b15zmfXACa https://t.co/aCY08xXtPw

Links:

Dr. John Cush RheumNow ( View Tweet)
Is there link between PsA & autoinflammatory Dz? Study of 120 #PsA pts found 31% w/ AID gene variants (AP1S3, PLCG2, NOD2, NLRP12, all monoallelic variants adn 1/2 genes assoc w/ autosomal dominant disorders. https://t.co/1cVFErPV6o https://t.co/QtRHrZJLJI

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×